Aurobindo Pharma receives USFDA Approval for Omeprazole Delayed-release Capsules

20 Aug 2015 Evaluate

Aurobindo Pharma has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Omeprazole Delayed-release Capsules USP, 10mg, 20mg and 40mg (ANDA 203270). The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Prilosec Delayed-release Capsules, 10mg, 20mg and 40mg of AstraZeneca Pharmaceuticals.

Omeprazole Delayed-release Capsules are indicated for short-term treatment of active duodenal ulcer in adults. The product has an estimated market size of US$422 Million for the twelve months ending June 2015 according to IMS. This is the 43rd ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-betalactam products. Aurobindo now has a total of 208 ANDA approvals (180 Final approvals including 9 from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA.

Aurobindo Pharma, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. 

Aurobindo Pharma Share Price

1167.20 -5.10 (-0.44%)
19-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.55
Dr. Reddys Lab 1166.45
Cipla 1391.20
Zydus Lifesciences 881.10
Lupin 2178.20
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×